Related Experiment Video

Updated: Jun 5, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Analysis of Clinical Characteristics and Treatment Efficacy in the Korean Hepatitis B Cohort

TaeYong Kim1, Jae Seung Lee2, Oeuk Jeong1

  • 1Division of Clinical Research, Center for Emerging Virus Research, National Institute of Infectious Diseases, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea.

Public Health Weekly Report
|June 4, 2026
PubMed

Insights

The Korea hepatitis B cohort study tracked 2,799 individuals with chronic hepatitis B virus (HBV) infection. Effective antiviral therapy improved chronic hepatitis B management, informing future public health policies in the Republic of Korea.

Area of Science:

  • Hepatology
  • Epidemiology
  • Public Health

Background:

  • Chronic hepatitis B virus (HBV) infection poses a significant public health challenge in the Republic of Korea (ROK).
  • Understanding the epidemiological characteristics and treatment outcomes of HBV is crucial for effective disease control.

Purpose of the Study:

  • To analyze the epidemiological features of chronic hepatitis B in the ROK.
  • To evaluate treatment outcomes and identify factors influencing disease progression.
  • To provide evidence for HBV control strategies and national policy development.

Main Methods:

  • A prospective observational cohort study involving adults (≥19 years) with chronic HBV infection.
  • Data collection included antiviral treatment, treatment adherence, and liver-related outcomes (e.g., hepatocellular carcinoma).
  • Longitudinal blood samples were collected from consenting participants over a 6- to 12-month interval.

Main Results:

  • 2,799 participants' data were analyzed from 2015-2024.
  • Epidemiological patterns aligned with existing trends in the ROK.
  • Effective antiviral therapy was linked to improved management of chronic hepatitis B.

Conclusions:

  • Continued monitoring of the cohort is essential for understanding long-term outcomes.
  • Study findings will inform revisions of national clinical practice guidelines.
  • Evidence generated will support the development of public health policies for HBV control in the ROK.
Abstract

Keywords:
Cohort studiesHepatitis BHepatitis B virusHepatitis B, chronic

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...